AU2014361822A1 - Treating brain disorders and biomarkers related thereto - Google Patents

Treating brain disorders and biomarkers related thereto Download PDF

Info

Publication number
AU2014361822A1
AU2014361822A1 AU2014361822A AU2014361822A AU2014361822A1 AU 2014361822 A1 AU2014361822 A1 AU 2014361822A1 AU 2014361822 A AU2014361822 A AU 2014361822A AU 2014361822 A AU2014361822 A AU 2014361822A AU 2014361822 A1 AU2014361822 A1 AU 2014361822A1
Authority
AU
Australia
Prior art keywords
disorder
patient
brain
glyx
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014361822A
Other languages
English (en)
Inventor
Joseph Moskal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of AU2014361822A1 publication Critical patent/AU2014361822A1/en
Priority to AU2019264583A priority Critical patent/AU2019264583A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
AU2014361822A 2013-12-13 2014-12-15 Treating brain disorders and biomarkers related thereto Abandoned AU2014361822A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019264583A AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361915835P 2013-12-13 2013-12-13
US61/915,835 2013-12-13
PCT/US2014/070340 WO2015089503A2 (en) 2013-12-13 2014-12-15 Methods of treating brain disorders or identifying biomarkers related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019264583A Division AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Publications (1)

Publication Number Publication Date
AU2014361822A1 true AU2014361822A1 (en) 2016-07-28

Family

ID=53371976

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014361822A Abandoned AU2014361822A1 (en) 2013-12-13 2014-12-15 Treating brain disorders and biomarkers related thereto
AU2019264583A Abandoned AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019264583A Abandoned AU2019264583A1 (en) 2013-12-13 2019-11-13 Treating brain disorders and biomarkers related thereto

Country Status (9)

Country Link
US (1) US20160345855A1 (https=)
EP (2) EP3079579A4 (https=)
JP (2) JP2017500306A (https=)
CN (2) CN106102762A (https=)
AU (2) AU2014361822A1 (https=)
CA (1) CA2933372A1 (https=)
IL (2) IL246148A0 (https=)
MX (1) MX2016007716A (https=)
WO (1) WO2015089503A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018530593A (ja) * 2015-10-16 2018-10-18 ノースウェスタン ユニバーシティ 統合失調症、双極性障害、認知障害及び大うつ病性障害の治療のための非定型的抗精神病薬ならびにｎｍｄａ調節剤の医薬品の組み合わせ
US20220024976A1 (en) * 2019-01-11 2022-01-27 Naurex Inc. Salt and crystalline forms of rapastinel
CN110123342B (zh) * 2019-04-17 2021-06-08 西北大学 一种基于脑电波的网瘾检测方法及系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20050273017A1 (en) * 2004-03-26 2005-12-08 Evian Gordon Collective brain measurement system and method
US20090253982A1 (en) * 2006-04-03 2009-10-08 Jiongjiong Wang Assessing subject's reactivity to psychological stress using fmri
CN101505745A (zh) * 2006-06-15 2009-08-12 玛尔斯有限公司 改善认知功能的方法和组合物
US8951968B2 (en) * 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
PL2485751T3 (pl) * 2009-10-05 2014-10-31 Univ Northwestern GLYX-13 do stosowania w sposobie leczenia depresji opornej na leczenie
US20140107037A1 (en) * 2011-04-27 2014-04-17 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
WO2013106084A1 (en) * 2012-01-09 2013-07-18 Takeda Pharmaceutical Company Limited Methods and drug products for treating alzheimer's disease

Also Published As

Publication number Publication date
EP3721799A1 (en) 2020-10-14
WO2015089503A3 (en) 2015-10-01
JP2020007333A (ja) 2020-01-16
EP3079579A2 (en) 2016-10-19
CN106102762A (zh) 2016-11-09
AU2019264583A1 (en) 2019-12-05
IL246148A0 (en) 2016-07-31
CA2933372A1 (en) 2015-06-18
US20160345855A1 (en) 2016-12-01
MX2016007716A (es) 2017-03-31
WO2015089503A2 (en) 2015-06-18
IL276431A (en) 2020-09-30
CN111920412A (zh) 2020-11-13
JP2017500306A (ja) 2017-01-05
EP3079579A4 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
EP2813236A1 (en) GLYX for use in the treatment of depression or anxiety
CN101977606A (zh) 使用nmda nr2b亚型选择性拮抗剂来治疗病症的方法
AU2019264583A1 (en) Treating brain disorders and biomarkers related thereto
US20130274289A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
AU2018286608A1 (en) A2a antagonists as cognition and motor function enhancers
JP2020128391A (ja) Ｎｍｄａ調節剤を使用するうつ病の治療方法
US20250179044A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
JP2017506233A (ja) クレアチン、ω−３脂肪酸、及びシチコリンの組み合わせ
JP2018065829A (ja) シグマ受容体に仲介される障害を処置するための環状アミド誘導体の使用の方法
US20120046302A1 (en) Methods of treating cns disorders
WO2020118282A1 (en) Methods, compositions and kits for treating multiple sclerosis and other disorders
WO2008137571A1 (en) Methods of treating neurodegenerative diseases
Rabins et al. Pathophysiology of involuntary emotional expression disorder
WO2010126527A1 (en) Methods of treating cns disorders
HK40040750A (en) Methods of treating brain disorders or identifying biomarkers related thereto
KR20230167032A (ko) 인지 장애의 치료를 위한 화합물
AU4301699A (en) Use of 4-piperidinemethanol derivatives in treatment of neurodevelopmental disorders
US20190351006A1 (en) Methods of administration of nmda receptor agonists
CA2933730C (en) Benzodioxol derivatives for use in the treatment of attention deficit and/or hyperactivity
Toyohara et al. Roles of σ1 receptors in the mechanisms of action of CNS drugs
El Yacoubi et al. Theobromine and tryptophan alone or in association lack potential antidepressant-like effects whereas chronic paroxetine is effective in a genetic mouse model of depressive disorder
Iannitelli et al. P. 3. d. 010 Clozapine or haloperidol in the rat affect the neurotrophins' levels in the brain and blood stream
HK1237649A1 (zh) Nmdar调节化合物的组合
KR20070045647A (ko) 우울증 치료 약물 제조에 있어서 신경 성장 인자의 용도

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted